The inhibitory effect of somatostatin on various endocrine and exocrine secretions explains why long-acting pharmacologically active analogs are being used increasingly in the clinical practice. In fact they are considered first-line drugs in the therapy of pituitary adenomas, carcinoids and gastroenteropancreatic neuroendocrine tumors, and are currently used in the emergency room for gastrointestinal bleeding. In addition scintigraphic methods that employ labeled somatostatin analogs (such as Octreoscan) are very helpful for staging of neuroendocrine tumors and lymphomas. Somatostatin receptors are expressed on the cell surface of both neuroendocrine and non-neuroendocrine tumors, such as breast and colon cancer, as well as lymphomas, and can mediate an antiproliferative effect. A role for somatostatin analogs in tumor cell growth is at present under investigation. In this review we report on the recent acquisitions in the field.
|Translated title of the contribution||Somatostatin analogs: An update|
|Number of pages||5|
|Publication status||Published - 1994|
ASJC Scopus subject areas
- Internal Medicine